Somatostatin Analogs in Patients with Multiple Endocrine Neoplasia Type 1 and Zollinger-Ellison Syndrome: Efficacy and Safety Abstract #1756

Introduction: Zollinger-Ellison syndrome (ZES) can cause severe complications. In multiple endocrine neoplasia type 1 (MEN1) related ZES, surgery has a controversial role and proton pump inhibitors (PPI) are usually first-line therapy, although some concerns regarding long-term use. Somatostatin analogs (SSA) both reduce hypergastrinemia and have an antiproliferative role.
Aim(s): Aim of this study is to evaluate efficacy and safety of PPI and SSA in MEN1 related ZES.
Materials and methods: Eighteen pts with MEN1 related ZES were retrospectively evaluated (12 m, 6 f, mean age 36 yrs) for a median follow-up of 104 months (range 6-203). Gastrinoma was located in pancreas(7), pancreas and duodenum(7), duodenum(4). All pts were treated with PPI only for at least 6 months (median 12, range 6-19), afterwards SSA were added.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD Roberta Modica

To read results and conclusion, please login ...

Further abstracts you may be interested in

No result